Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences receives another chunk of money from placement

Medtech firm Pressure BioSciences has received an additional $1.1mln from its private placement initiative. The funds raised via the proposed $5mln share placing have now risen to $3.28mln.
Pressure BioSciences receives another chunk of money from placement
With the funds received to date, the company has eliminated some 70% of its ariable rate convertible debt.

Medtech firm Pressure BioSciences (OTCQB:PBIO) has received an additional $1.1mln from its private placement initiative.

The funds raised via the proposed $5mln share placing have now risen to $3.28mln. One or two more additional tranches are expected to complete in the near future, the company told investors.

As per the subscription agreement, Pressure BioSciences will issue senior secured convertible debentures at a fixed conversion price of $0.28 per restricted common share, and common stock purchase warrants exercisable at US$0.40 per share.

“The priorities for the use of funds from the offering remain: (i) to expand the company’s marketing and sales capabilities, including a sizeable increase in the number of the Company’s marketing and sales personnel; (ii) to increase the company’s manufacturing and operational capabilities; (iii) to ready the company for a potential uplisting to a regulated exchange in the near future; and (iv) to retire all variable rate convertible debt (“VRCD”) we took on to help facilitate growth prior to additional equity capital being raised," stressed Richard Schumacher, president and chief executive officer of Pressure BioSciences.

"With the funds received to date, we have eliminated approximately 70% of all the VRCD we had as of the close of the 2015 second quarter. It is expected that cash received from additional closings that may occur in the near future will be used to eliminate all remaining VRCD debt,” he added.

PBIO is developing pressure cycling technology-based instruments and consumables for a number of areas in scientific research, including drug discovery and design, cancer and other disease/disorder detection, and the analysis of microorganism populations in soil.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
scientist looking through microscope
April 12 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use